Results 161 to 170 of about 5,693 (231)

SGLT2 inhibitors, but not GLP-1 receptor agonists, reduce incidence of gout in people living with type 2 diabetes across the therapeutic spectrum

open access: yes
Purpose: This study aimed to evaluate the relative association between sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1Ra) with the incidence of gout in patients with type 2 diabetes (T2D) using real-
Alam, Uazman   +8 more
core   +1 more source

Effect of combination pioglitazone with SGLT2i or GLP-1 RA on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database

open access: yes
Aims. To evaluate the efficacy and cardiovascular outcomes of combination pioglitazone with either glucagon-like peptide 1 receptor agonist (GLP-1 RA) or sodium-glucose cotransporter-2 inhibitor (SGLT2i) in individuals with type 2 diabetes (T2D) by ...
Alam, Uazman   +7 more
core   +1 more source

Patient factors associated with tracheoesophageal prosthesis complications: A retrospective TriNetX study

open access: yesAmerican Journal of Otolaryngology
Sandhya Ganesan   +6 more
openaire   +1 more source

Survival in patients with monoclonal gammopathy of unknown significance after transcatheter aortic valve replacement: a global retrospective propensity-matched real-world analysis. [PDF]

open access: yesCardiooncology
Oelschläger L   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy